Century Therapeutics (IPSC) shares were down 3.6% in recent Monday trading after Leerink Partners downgraded the biotechnology company's stock to market perform from outperform, with a $7 price target.
Trading volume stood at over 2 million shares, compared with a daily average of nearly 904,000.
Price: 0.46, Change: -0.02, Percent Change: -3.60